Hercules Capital is still recommended as a Buy due to its strong credit quality and steady income stream, offering an 11.1% yield with well-covered distributions. However, confidence has decreased since August because net investment income per share fell from $0.50 in Q2 to $0.47 in Q3, mainly due to lower prepayments and higher debt costs. Leverage has increased due to slower repayments, but non-accruals remain minimal and internal credit grades are improving. Investors are advised to hold for income rather than growth, as fundamentals remain clean but growth is lacking.
Hercules Capital is noted for its 11.1% dividend yield, providing a steady income stream despite recent earnings softness. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 05, 2026 17:11 WIB: out of 142 priced US Financials stocks tradable on Pluang, 89 rose and 46 fell today. Notable movers include SEZL (Sezzle Inc) at USD 172.84 with a +26.45% change, AVAT (Avalanche Treasury Corporation Class A Common Stock) at USD 1.00 with a +6.08% change, and PSEC (Prospect Capital Corporation) at USD 1.51 with a +4.86% change and strong buy interest (97% buy orders).
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
